Get the Stockscreener App
1.71
5.00%
-0.09
After Hours:
1.78
0.07
+4.09%
Caribou Biosciences Inc stock is traded at $1.71, with a volume of 1.07M.
It is down -5.00% in the last 24 hours and up +15.54% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
See More
Previous Close:
$1.80
Open:
$1.79
24h Volume:
1.07M
Relative Volume:
0.93
Market Cap:
$159.83M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-1.1712
EPS:
-1.46
Net Cash Flow:
$-104.90M
1W Performance:
-14.07%
1M Performance:
+15.54%
6M Performance:
-8.56%
1Y Performance:
+48.70%
1-Day Range:
$1.665
$1.815
1-Week Range:
$1.665
$2.01
52-Week Range:
$0.66
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.71 | 168.24M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
CRBU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Caribou Biosciences (CRBU) to Release Earnings on Monday - MarketBeat
Insider Sell: Timothy Kelly Sells Shares of Caribou Biosciences Inc (CRBU) - GuruFocus
Caribou Biosciences Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Caribou Biosciences (CRBU) CTO sells 6,228 shares in open-market trade - Stock Titan
7 Top Gene-Editing Stocks to Buy - US News Money
Caribou Biosciences (NASDAQ: CRBU) notice to sell 6,938 vested shares - Stock Titan
Caribou Biosciences (NASDAQ: CRBU) files Rule 144 to sell 6,938 shares - Stock Titan
Timothy Kelly sells 3,147 CRBU shares; proposed sale of 6,228 restricted shares (CRBU) - Stock Titan
Decliners Report: Is Roivant Sciences Ltd stock undervalued right nowJuly 2025 Update & Daily Growth Stock Tips - baoquankhu1.vn
Caribou Biosciences (NASDAQ:CRBU) Insider Ruhi Ahmad Khan Sells 6,938 Shares - MarketBeat
Caribou Biosciences CLO sold $13,598 in CRBU stock - Investing.com Australia
Caribou Biosciences CLO sold $13,598 in CRBU stock By Investing.com - Investing.com Canada
Caribou Biosciences CTO Kelly sells $6.1k in shares By Investing.com - Investing.com Canada
Khan, Caribou Biosciences CBO, sells $13598 in stock - Investing.com Australia
Khan, Caribou Biosciences CBO, sells $13598 in stock By Investing.com - Investing.com Canada
Caribou Biosciences (CRBU) CBO awarded stock options, sells shares for tax - Stock Titan
Caribou (CRBU) CMO gets 247,500 options, small tax-related sale - Stock Titan
Growth Value: Is Caribou Biosciences Inc benefiting from interest rate changesMarket Risk Report & Intraday High Probability Alerts - baoquankhu1.vn
Earnings Risk: Is Magyar Bancorp Inc stock a falling knife or bargain buyJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - baoquankhu1.vn
Caribou Biosciences Details Pivotal-Ready Vispa-cel Plan, Flags Need for More Capital at Citi Summit - MarketBeat
Should you avoid Caribou Biosciences Inc. stock right now2025 Earnings Impact & Weekly Watchlist for Consistent Profits - mfd.ru
Volume Report: Is NCIQ stock forming a cup and handleSwing Trade & Weekly High Potential Alerts - baoquankhu1.vn
Short Squeeze: How does Caribou Biosciences Inc compare to its peersInflation Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Director at Caribou Biosciences (CRBU) awarded option for 45,000 shares - Stock Titan
Caribou Biosciences (CRBU) CEO receives large new equity grants - Stock Titan
Is Caribou Biosciences Inc. stock a top performer YTDWeekly Trade Report & Low Drawdown Momentum Trade Ideas - mfd.ru
Caribou Biosciences (CRBU)’s CB-011 may reach $734 million in peak 2040 sales, according to Clear Street - MSN
Caribou Biosciences (CRBU)’s CB-011 May Reach $734 Million in Peak 2040 Sales, According to Clear Street - Yahoo Finance
Caribou Biosciences (CRBU)'s CB-011 May Reach $734 Million in Peak 2040 Sales, According to Clear Street - Finviz
Is Caribou Biosciences Inc. stock risky to hold nowJuly 2025 Outlook & AI Forecasted Stock Moves - mfd.ru
Can Caribou Biosciences Inc. stock hit record highs again2025 Key Highlights & AI Powered Market Trend Analysis - mfd.ru
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost Per Sample - marketscreener.com
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample - BioSpace
Will Caribou Biosciences Inc. stock benefit from infrastructure spendingQuarterly Profit Report & Real-Time Volume Spike Alerts - mfd.ru
Caribou Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Will Caribou Biosciences Inc. stock benefit from upcoming earnings reportsMarket Sentiment Summary & Weekly Return Optimization Plans - mfd.ru
Merger Talk: Is Caribou Biosciences Inc stock showing strong momentum2025 Trading Volume Trends & Verified Stock Trade Ideas - baoquankhu1.vn
CRISPR-focused Caribou set for fireside chats at 2 investor events - Stock Titan
Caribou Biosciences, Inc. (CRBU) Presents at 2026 Tandem Meetings of ASTCT and CIBMTRSlideshow - Seeking Alpha
What is Brookline Cap M's Forecast for CRBU FY2030 Earnings? - MarketBeat
Research Analysts Offer Predictions for CRBU FY2030 Earnings - MarketBeat
Bond Watch: How does Caribou Biosciences Inc compare to its peersLayoff News & AI Enhanced Trading Signals - baoquankhu1.vn
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), Caribou Biosciences (CRBU) and Boston Scientific (BSX) - The Globe and Mail
Caribou Biosciences (NASDAQ:CRBU) Shares Up 3.8%What's Next? - MarketBeat
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR - Investing News Network
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR® - The Manila Times
Off-the-shelf CAR-T data in lymphoma and myeloma head to 2026 Tandem - Stock Titan
Clear Street Initiates Caribou Biosciences(CRBU.US) With Buy Rating, Announces Target Price $13 - 富途牛牛
Caribou Biosciences a new buy at Clear Street on CAR-T pipeline - Seeking Alpha
Clear Street Initiates Coverage of Caribou Biosciences (CRBU) with Buy Recommendation - Nasdaq
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):